The performance of the first three quarters of the pharmaceutical industry is in full swing

Source: China Securities Journal 2013-10-11 in the first three quarters of 2013, the fundamentals of pharmaceutical listed companies showed an overall positive trend As of October 9, a total of 60 pharmaceutical listed companies have issued the third quarter performance forecast, of which 48 Enterprises with performance forecast, profit and loss recovery account for 80% 8 according to statistics, as of October 9, 60 pharmaceutical listed companies have issued the third quarter performance forecast Among them, there are 39 enterprises with increased performance in advance, 8 enterprises with decreased performance in advance, 4 enterprises with loss in advance, 6 enterprises with profit in advance and 3 enterprises with loss in return Among the pre growth enterprises, there are four companies with a performance growth rate of more than 100% They are: Duyiwei, Jiaying pharmaceutical, Jingxin pharmaceutical and Jiuzhitang Most of the reasons for the performance growth given by these companies are the growth of main business income Among the 48 pharmaceutical listed companies whose performance is expected to be good, 21 are expected to be good, accounting for 91.3% of the Chinese medicine listed companies whose performance is announced Among them, the performance of Jiaying pharmaceutical, Duyiwei, taiantang and Yiling pharmaceutical has increased by more than 50%, and some of the products of the above companies have been selected in 2012 The national essential drugs catalogue (EDITION) in resulted in an increase in sales revenue There are 5 biological products companies with good performance forecast, accounting for 83.3% of the listed companies of biological products that announce the performance forecast; 10 chemical companies, accounting for 83.3% of the listed companies of chemical products that announce the performance forecast; 7 medical devices, commercial and service companies, accounting for 83.3% of the listed companies of medical devices, commercial and service that announce the performance forecast 100% 9 pharmaceutical companies have accelerated their performance Although the overall performance of pharmaceutical listed companies is flying red, most pharmaceutical companies only continue the momentum of profit growth since this year, and not many can achieve rapid performance development Data statistics show that the lower limit of the pre increase range in the first three quarters of nine pharmaceutical listed companies exceeded the semi annual performance growth This means that the profitability of these companies increased significantly in the third quarter, which promoted the growth of performance The 9 listed pharmaceutical companies are Jiaying pharmaceutical, Jiuzhitang, Yabao pharmaceutical, Daan gene, Asia Pacific pharmaceutical, Yunnan Baiyao, Yiling pharmaceutical, Yuheng pharmaceutical and Hualan bio Among them, Jiaying pharmaceutical has the most significant performance improvement According to the semi annual report, the net profit of Jiaying pharmaceutical increased by 382.21% year on year, while the expected increase in the first three quarters was 985% - 1084% The reason for the sharp increase in the first three quarters' performance of Jiaying pharmaceutical was that, in addition to the obvious increase in the sales revenue of the company's products, the net profit base of the first three quarters of last year was only 101.33% Jiuzhitang became a representative of getting rich by foreign capital Jiuzhitang's first three quarter performance forecast shows that the company's profit is expected to be 168 million yuan to 194 million yuan from January to September, up 95% - 125% year-on-year, while the company's semi annual performance growth is only 18.90% The main reason for Jiuzhitang's net profit growth is that the company sold 2.25 million shares of Kelun Pharmaceutical Co., Ltd from August 7 to 13, and obtained investment income of about 99.86 million yuan As a leading enterprise in the pharmaceutical industry, Yunnan Baiyao's performance acceleration is the most remarkable The expected growth rate of Yunnan Baiyao in the first three quarters reached 48.71% - 63.85%; the net profit also increased from 1.123 billion yuan in the same period of 2012 to 1.670-1.84 billion yuan According to Yunnan Baiyao, the reason for the change in performance is that the industrial and commercial registration of the transfer transaction of Yunnan Baiyao Real Estate Co., Ltd has been completed in July, and it is expected to achieve some of the relevant profits In addition to the above-mentioned nine enterprises with accelerated growth in advance, Asia Pacific pharmaceutical industry with a loss in performance also deserves attention The Asia Pacific pharmaceutical industry lost 7.78 million yuan in the first half of the year, while the performance forecast for the first three quarters is 4 million yuan to 7 million yuan That means the Asia Pacific pharmaceutical industry made a profit in the third quarter.